Details:
CANbridge is developing CAN106, in conjunction with WuXi Biologics (2269.HK), a global company with leading open-access biologics technology platforms, as part of a strategic partnership for the development of rare disease therapeutics.
Lead Product(s): CAN106
Therapeutic Area: Hematology Product Name: CAN106
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: WuXi Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2020